Business Context and Reporting Period
This Form 6-K serves as an Annual Information Update for GlaxoSmithKline plc (GSK) covering the 12-month period ended March 30, 2007. The filing acts as a summary index of regulatory announcements, corporate filings, and shareholder documents rather than a standalone financial report. GSK is a foreign issuer reporting under Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being contained within the "Annual Report and Accounts" and "Final Results" documents published on March 2, 2007, and February 8, 2007, respectively, but the data itself is not included in this filing.
Material Changes and Corporate Activity
While specific financial variances are not detailed, the filing highlights significant corporate actions and regulatory events during the period:
- Acquisitions: GSK announced the acquisition of Praecis (December 21, 2006), Domantis (December 8, 2006), and CNS Inc (October 9, 2006).
- Share Repurchases: The company maintained an active buyback program, with multiple announcements regarding transactions in own shares and returns filed with Companies House for treasury holdings throughout the year.
- Regulatory Approvals: Notable milestones included FDA approval for Tykerb (March 14, 2007) and a US filing for Cervarix (March 30, 2007).
- Legal Settlements: The company announced a settlement regarding an IRS tax dispute on September 11, 2006.
- Product Data: Positive results were reported for the Avandia ADOPT study on December 4, 2006.
Guidance, Outlook, and Risks
This document does not provide forward-looking guidance, management commentary on future performance, or a detailed risk assessment. It explicitly states that the information is a summary of past publications and that some data may now be out of date. Investors are directed to the Annual Report and Accounts for comprehensive management discussion and analysis.
Investor Verification Checklist
- Verify the full financial results (revenue, net income, EPS) in the "Annual Report and Accounts" dated March 2, 2007.
- Review the "Final Results" announcement from February 8, 2007, for detailed performance metrics.
- Confirm the financial impact and integration status of the acquisitions of Praecis, Domantis, and CNS Inc.
- Assess the commercial implications of the FDA approval for Tykerb and the Cervarix US filing.
- Examine the terms and financial impact of the IRS tax dispute settlement announced in September 2006.